基于网络药理学的中药研究及中成药二次开发模式探讨  

Chinese Medicine Research and the Secondary Development Model of Traditional Chinese Medicine Based on Network Pharmacology

作　　者：辛卫云 白明[1] 苗明三[1] 

机构地区：[1]河南中医学院,河南郑州450046

出　　处：《中医学报》2016年第1期92-95,共4页Acta Chinese Medicine

基　　金：道地药材深加工河南省工程实验室基金项目(2012-1431-10);河南省高校科技创新团队基金项目(2012IRTSTHN011);郑州市科技创新团队基金项目(131PCXTD612);河南中医学院中药新药创制与道地药材深加工协同创新中心基金项目{〔2012〕188-2}

摘　　要：网络药理学已用于药物、疾病以及药物-疾病网络的构建,并初步体现了网络药理学的独特优势。但未来发展仍面临诸多挑战,主要体现在:1大部分图谱信息来源于不同的实验条件,网络药理学属于定量药理学或药物设计的学科范畴,其研究基础是从实验中获得的图谱数据,但由于目前用于网络计算的大部分图谱信息来源于不同的实验条件,在计算两个相似或相同的疾病时,具有很低的相关性,呈现出假阴性;2已经评价的小分子化合物及其作用靶点数量均有限,鉴于生物医学的发展进程,目前仅对部分小分子化合物在少数靶点蛋白上进行了筛选评价,因此不能揭示其完整的药理作用;3公用数据库的信息有限,目前国际上可以共享的数据库信息均倾向于某些热点研究领域,因此其信息均存在不同程度的局限性。Network pharmacology has been used in the construction of drugs,disease and drug-disease networks with unique advantages. However,currently many challenges exist in the following aspects： 1Most of the map information are obtained from different experiment conditions. Belonging to the areas of quantitative pharmacology and drug design,research of network pharmacology is based on data obtained from the Atlas experiment. However,as most of the network map calculation information are derived from different experiment conditions,very low correlation or even a false negative is presented in the calculation of two similar or identical diseases. 2There are limited number of small molecule compounds and their targets has been evaluated. Therefore the pharmacological effect of the small molecule compounds can not be fully revealed. 3The information obtained from the public database is quite limited,and only the database information in some hot research field can be shared internationally.

关 键 词：中成药二次开发模式 网络药理学 中药研究 

分 类 号：R284.2[医药卫生—中药学]